Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Eisai Co., Ltd    4523   JP3160400002

EISAI CO., LTD (4523)
My previous session
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Eisai : clinches Merck deal to develop and sell cancer drug, shares soar

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/08/2018 | 08:30am CEST
Eisai Co Ltd Representative Corporate Officer and CEO Haruo Naito attends a news conference at the company headquarters in Tokyo

NEW YORK/TOKYO (Reuters) - Merck & Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses.

The deal, under which Lenvima will be developed for several types of cancer alone and in combination with Merck's immunotherapy Keytruda, could be worth up to $5.76 billion (4.14 billion pounds) to Eisai, but most of that would be contingent on eventual sales.

Eisai shares surged 10 percent on the news, with the Japanese drugmaker saying Lenvima may become a blockbuster drug generating annual sales of at least $1 billion in the year ending March 2021.

U.S. drugmaker Merck will be entitled to half of all global Lenvima sales revenue, even for its already approved uses for thyroid cancer and in combination with another drug for kidney cancer.

The deal is similar to a multibillion-dollar oncology collaboration Merck struck with AstraZeneca Plc on its cancer drug Lynparza and another medicine last July.

"Like the Lynparza deal with AstraZeneca, this starts to really broaden out Merck's portfolio," Frank Clyburn, head of Merck's commercial oncology business, said in an interview. "And Merck will start to receive revenue right away."

Under the deal, Eisai will receive an upfront payment of $300 million and up to $650 million for certain option rights through March 2021. Eisai could receive another $385 million in clinical and regulatory milestones, while Merck will receive $450 million as reimbursement for research and development costs.

The collaboration gives Eisai access to Merck's R&D and sales clout as well as a means of maximizing the potential of Lenvima in combination with the leading immunotherapy drug.

Following positive trial data showing that Lenvima with Keytruda led to tumor shrinkage in 63 percent of advanced kidney cancer patients, the combination received breakthrough designation from the U.S. Food and Drug Administration.

The combination also appeared to enhance the impact of Keytruda on advanced kidney cancer.

Breakthrough status is a designation given to treatments demonstrating substantial improvement over existing therapies in treating a serious or life threatening illness.

The companies said they will develop the combination for 11 different potential uses across six other cancer types, including skin cancer and bladder cancer.

"It makes sense ... to try to develop the drug to the full extent possible as monotherapy and in combination with Keytruda," Roger Perlmutter, president of Merck Research Laboratories, said in an interview.

Lenvima, an oral drug known chemically as lenvatinib, was discovered by Eisai scientists and belongs to a class of medicines known as tyrosine kinase inhibitors that block the blood vessel supply to tumors and tumor growth.

The injection of funds following the deal will be used to accelerate research and development of treatments for Alzheimer's disease and cancer, Eisai Chief Executive Haruo Naito told a news conference in Tokyo.

Eisai's shares, currently worth some $17 billion, have been hit in recent months by setbacks for two Alzheimer's drugs in development with Biogen Inc.

One drug, BAN2401, failed to meet the main goal of a mid-stage trial, Biogen said in December. In February, the U.S. drugmaker said it was enrolling more patients for its late-stage trial drug aducanumab, heightening concerns about the challenges of Alzheimer's drug studies.

(Reporting by Bill Berkrot in New York and Sam Nussey in Tokyo; Additional reporting by Chang-Ran Kim, Minami Funakoshi in Tokyo; Editing by Lisa Shumaker and Edwina Gibbs)

By Bill Berkrot and Sam Nussey

Stocks treated in this article : Merck and Company, Eisai Co., Ltd
Stocks mentioned in the article
ChangeLast1st jan.
EISAI CO., LTD -1.03% 10545 End-of-day quote.62.31%
MERCK AND COMPANY -0.62% 69.98 Delayed Quote.24.36%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EISAI CO., LTD
09/17EISAI : LSTM led partnership receives funding to develop drug for treating two n..
AQ
09/07MERCK AND : Eisai and Merck Announce China National Medical Products Administrat..
AQ
09/07EISAI : and Merck Receive Chinese Agency Approval of Lenvima
AQ
09/06EISAI : Stephen Davies Appointed Vice President, Eisai Strategic Information Sys..
AQ
09/06EISAI : and Merck & Co., Inc., Kenilworth, Nj., USA. Announce China National Med..
AQ
09/05EISAI : And Merck & Co. Announce China NMPA Approval of First Approval for LENVI..
AQ
09/04EISAI : Notice regarding partial label change for vascular embolization device d..
AQ
09/04EISAI : Notice Regarding Partial Label Change for Vascular Embolization Device D..
AQ
09/03EISAI : Receives Approval for Partial Label Change for Vascular Embolization Dev..
AQ
08/31EISAI : Biogen and Eisai report new results from Phase lb trial of aducanumab
AQ
More news
News from SeekingAlpha
09/10PHARMACEUTICAL/BIOPHARMA SEPTEMBER M : Vanishing Uncertainty 
09/10WEEK IN REVIEW : Jiangsu Hansoh To Raise Up To $3 Billion In Hong Kong IPO 
09/05Eisai's Lenvima OK'd in China for liver cancer 
09/02WEEK IN REVIEW : Nearly $1 Billion In Cross-Border China Biopharma Deals 
08/28Biogen's Alzheimer's candidate aducanumab maintains risk-benefit profile in l.. 
Financials (JPY)
Sales 2019 630 B
EBIT 2019 -
Net income 2019 56 247 M
Finance 2019 122 B
Yield 2019 1,42%
P/E ratio 2019 52,78
P/E ratio 2020 56,22
EV / Sales 2019 4,77x
EV / Sales 2020 4,84x
Capitalization 3 127 B
Chart EISAI CO., LTD
Duration : Period :
Eisai Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 11 370  JPY
Spread / Average Target 7,8%
EPS Revisions
Managers
NameTitle
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer & Chief IR Officer
Hideki Hayashi Chief Information Officer
Nobuo Deguchi Director
Noboru Naoe Director
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD62.31%27 867
JOHNSON & JOHNSON0.59%375 479
PFIZER20.13%252 129
NOVARTIS-0.80%215 800
ROCHE HOLDING LTD.-4.06%212 015
MERCK AND COMPANY24.36%187 284